Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
50.08
+0.96 (1.95%)
At close: Jun 26, 2026, 4:00 PM EDT
50.00
-0.08 (-0.16%)
After-hours: Jun 26, 2026, 7:57 PM EDT
Enliven Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Enliven Therapeutics stock have an average target of 59.56, with a low estimate of 45 and a high estimate of 80. The average target predicts an increase of 18.93% from the current stock price of 50.08.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Enliven Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 8 | 8 | 8 | 9 | 10 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 8 | 8 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $59 | Buy | Maintains | $59 | +17.81% | Jun 15, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 12, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $80 | Buy | Maintains | $80 | +59.74% | Jun 12, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $60 | Buy | Reiterates | $60 | +19.81% | Jun 11, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $45 | Buy | Reiterates | $45 | -10.14% | Jun 11, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
7.14K
EPS This Year
-1.75
from -1.83
EPS Next Year
-2.43
from -1.75
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | 50,000 | |
| Avg | n/a | 7,140 | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | 600.3% |
| Avg | - | - |
| Low | - | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.37 | -1.71 | |
| Avg | -1.75 | -2.43 | |
| Low | -1.98 | -2.90 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.